Ascendis Pharma received accelerated FDA approval for Yuviwel, a weekly injection for achondroplasia in children. This breaks BioMarin's monopoly in the space, as their competing drug Voxzogo requires daily shots. Analysts estimate around 40% of current patients might switch to the new drug due to the more convenient dosing schedule. Ascendis expects to launch in Q2 and will announce pricing soon, though they hinted it will be at a premium. BridgeBio is also in the mix with a pill treatment currently in development.